A common blood test for ovarian cancer is more likely to fall short for Black and Native American women, according to a new ...

Ovarian cancer is the fifth leading cause of cancer-related deaths among women in the U.S. However, the racial bias makes it ...

A common blood test may miss ovarian cancer in some Black and Native American patients, delaying their treatment, a new study ...

Black and American Indian patients are less likely to have elevated cancer antigen (CA)-125 levels at ovarian cancer ...

There is no national ovarian cancer screening programme as, according to the NHS, there is not a test that can reliably pick ...

A new study focusing on the common CA-125 blood test found that some patients were 23 percent less likely to show elevated cancer antigen levels at diagnosis.

The likelihood of having an elevated CA-125 level at ovarian cancer diagnosis was lower for American Indian, Asian, or Black patients versus White patients. HealthDay News — Black and American ...

A new study finds that a common blood test for ovarian cancer may miss some Black and Native American patients, delaying ...

Researchers examined CA-125 levels at diagnosis, defining them as elevated/borderline or negative/normal in 250,749 patients ...

In this cohort study of patients with ovarian cancer, American Indian and Black patients were 23% less likely to have an elevated ...

The researchers analyzed data from more than 200,000 women with ovarian cancer from 2004 through 2020 who’d had a CA-125 blood test. Black and Native American patients were 23% less likely to ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...